Sandoz Group AG Stock
Price
Target price
€71.58
€71.58
0.990%
0.7
0.990%
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Financial data and news for Sandoz Group
sharewise wants to provide you with the best news and tools for Sandoz Group, so we directly link to the best financial data sources.
Financials
News
Sandoz marks 80 years of antibiotics with call for urgent political action to safeguard European medicine security
Sandoz marks 80 years of antibiotics with call for urgent political action to safeguard European medicine security
Sandoz confirms European Commission approval for biosimilars Bysumlog® (insulin lispro) and Dazparda® (insulin aspart), strengthening position in diabetes
Sandoz confirms European Commission approval for biosimilars Bysumlog® (insulin lispro) and Dazparda® (insulin aspart), strengthening position in diabetes
Sandoz reports strong biosimilars growth in Q1 2026; full-year 2026 guidance confirmed
Sandoz reports strong biosimilars growth in Q1 2026; full-year 2026 guidance confirmed
Sandoz signs landmark agreement with Rwandan government to ensure stable provision of critical medicines across selected African markets
Sandoz signs landmark agreement with Rwandan government to ensure stable provision of critical medicines across selected African markets
Twenty years of biosimilar medicines: a milestone that continues to transform patient access worldwide
Twenty years of biosimilar medicines: a milestone that continues to transform patient access worldwide
Shareholders approve all resolutions proposed by Board of Directors at 2026 Annual General Meeting of Sandoz Group AG
Shareholders approve all resolutions proposed by Board of Directors at 2026 Annual General Meeting of Sandoz Group AG
Sandoz announces partnership agreement with Samsung Bioepis on up to five biosimilars, further expanding its leading pipeline to up to 32 assets
Sandoz announces partnership agreement with Samsung Bioepis on up to five biosimilars, further expanding its leading pipeline to up to 32 assets
Sandoz issues CHF 550 million in bonds and extends its USD 2 billion revolving credit facility by one year
Sandoz issues CHF 550 million in bonds and extends its USD 2 billion revolving credit facility by one year
Sandoz creates new global biosimilar development, manufacturing and supply unit, appoints industry veteran Armin Metzger to lead next phase of growth
Sandoz creates new global biosimilar development, manufacturing and supply unit, appoints industry veteran Armin Metzger to lead next phase of growth
Sandoz delivers strong full-year results; guidance for 2026 reflects an expected acceleration in growth
Sandoz delivers strong full-year results; guidance for 2026 reflects an expected acceleration in growth
Sandoz confirms European Commission approval for Ranluspec® (ranibizumab), further strengthening overall biosimilars leadership and position in ophthalmology
Sandoz confirms European Commission approval for Ranluspec® (ranibizumab), further strengthening overall biosimilars leadership and position in ophthalmology
Sandoz receives US FDA approval to expand Enzeevu® (aflibercept-abzv) label for multiple retinal indications
Sandoz receives US FDA approval to expand Enzeevu® (aflibercept-abzv) label for multiple retinal indications
Sandoz confirms European Commission approval of Ondibta® (insulin glargine), strengthening overall biosimilars leadership and position in diabetes
Sandoz confirms European Commission approval of Ondibta® (insulin glargine), strengthening overall biosimilars leadership and position in diabetes
Sandoz CEO, speaking at 44th Annual J.P. Morgan Healthcare Conference, will outline plans to capitalize on unprecedented ’golden decade’ of affordable medicines opportunity
Sandoz CEO, speaking at 44th Annual J.P. Morgan Healthcare Conference, will outline plans to capitalize on unprecedented ’golden decade’ of affordable medicines opportunity